MiMedx Group Downgraded by Northland Capital Partners to “Market Perform” (MDXG)
MiMedx Group (NASDAQ:MDXG) was downgraded by research analysts at Northland Capital Partners from an “outperform” rating to a “market perform” rating in a report released on Monday, AR Network reports. They currently have a $6.00 target price on the stock. Northland Capital Partners’ price target indicates a potential downside of 28.83% from the stock’s previous close.
A number of other firms have also recently commented on MDXG. Analysts at Northland Securities downgraded shares of MiMedx Group from an “outperform” rating to a “market perform” rating in a research note to investors on Monday. They noted that the move was a valuation call. Separately, analysts at Canaccord Genuity raised their price target on shares of MiMedx Group to $12.00 in a research note to investors on Friday, December 20th. Finally, analysts at Canaccord Genuity raised their price target on shares of MiMedx Group from $6.00 to $6.50 in a research note to investors on Thursday, October 31st. They now have a “buy” rating on the stock.
MiMedx Group (NASDAQ:MDXG) last released its earnings data on Wednesday, October 30th. The company reported $0.00 EPS for the quarter. The company had revenue of $16.10 million for the quarter, compared to the consensus estimate of $15.23 million. The company’s quarterly revenue was up 102.5% on a year-over-year basis.
MiMedx Group, Inc is a development-stage company. The Company is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.